GlobeNewswire Inc.··Upstream Bio, Inc.Upstream Bio to Unveil Extended VIBRANT Trial Data on Verekitug at AAAAI 2026
Upstream Bio will present expanded VIBRANT trial data on verekitug for chronic rhinosinusitis with nasal polyps at AAAAI 2026, including new efficacy analyses accounting for rescue therapy use.
UPBPhase 2 clinical trialmonoclonal antibody